Newton Charles W. 4
4 · Lyell Immunopharma, Inc. · Filed Aug 13, 2025
Insider Transaction Report
Form 4
Newton Charles W.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-08-11$10.53/sh−131$1,379→ 8,895 total - Sale
Common Stock
2025-08-12$10.34/sh−136$1,406→ 8,759 total
Holdings
- 10,000(indirect: By Trust)
Common Stock
Footnotes (8)
- [F1]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F2]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Fonn 4.
- [F3]Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F4]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
- [F5]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- [F6]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- [F7]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
- [F8]Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.